WAVEMAN · COMPANY

LPCN · Lipocine Inc.

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

LPCN

Name: Lipocine Inc. (LPCN) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Lipocine Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001535955

C-SUITE BUYING · 1☆ WATCH

INSIDER NET · 180D

$434.6K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

-82.3%

XBRL, annual

NET MARGIN

-487.1%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$434.6K over 180 days

more than 84% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

17 funds added or opened last quarter

below 72% of Pharma & Biotech

REVENUE

-82.3% year over year

below 90% of Pharma & Biotech

MARGIN

-487.1% net margin

below 82% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

1.4% of shares outstanding short · 3.6 days to cover · settled 2026-07-31

below 69% of Pharma & Biotech

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -16.6%

-16.6%12M

INSIDER BUY

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders are net buyers of their own stock.

The record shows a net $434.6K bought by insiders over 180 days, 17 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Lipocine Inc. insiders bought a net $434.6K of stock across 14 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Higuchi John W.

Director

BUY

2026-04-07

40,000.0

$81.2K

Higuchi John W.

Director

BUY

2026-04-06

123,000.0

$252.1K

Patel Mahesh V.

Chief Executive Officer

BUY

2026-04-06

25,000.0

$50.7K

Patel Mahesh V.

Chief Executive Officer

BUY

2026-04-02

25,000.0

$50.5K

Patel Mahesh V.

CEO and President

BUY

2023-05-25

8,706.0

$43.8K

14 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 9 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Squadron Capital Management LLC

810,000.0 sh

$2.1M

Ikarian Capital, LLC

508,556.0 sh

$1.3M

Eversept Partners, LP

294,989.0 sh

$755.2K

VANGUARD CAPITAL MANAGEMENT LLC

230,823.0 sh

$590.9K

BOOTHBAY FUND MANAGEMENT, LLC

140,487.0 sh

$359.6K

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

TIFF MULTI-ASSET FUND

$49.5K POSITION · AS OF 2026-03-31

0.0%

Fidelity Extended Market Index Fund

$284.9K POSITION · AS OF 2026-02-28

0.0%

VANGUARD EXTENDED MARKET INDEX FUND

$462.6K POSITION · AS OF 2026-03-31

0.0%

U.S. Social Core Equity 2 Portfolio

$6.4K POSITION · AS OF 2026-04-30

0.0%

Fidelity Nasdaq Composite Index Fund

$44.4K POSITION · AS OF 2026-02-28

0.0%

Dimensional U.S. Small Cap ETF

$14.1K POSITION · AS OF 2026-04-30

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 4 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release

Phase 2

0 ACTIVE

Phase 3

0 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Executive pay vs shareholder return · Mahesh Patel

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$986.3K

$1.1M

$488.4K

+19%

—

2024

$761.8K

$754.7K

$377.2K

-28%

—

2023

$860.3K

$720.1K

$353.4K

-59%

—

2022

$883.9K

$538.8K

$325.0K

-60%

—

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$2.0M	$11.2M	$-2.9M	$500.0K
OPERATING INCOME	$-10.4M	$-1.2M	$-17.9M	$-12.1M
NET INCOME	$-9.6M	$10.0K	$-16.4M	$-10.8M
EPS (DILUTED)	-1.69	—	-3.14	-2.15
OPERATING CASH FLOW	$-9.8M	$-1.2M	$-11.9M	$-12.0M
CASH	$5.2M	$6.2M	$4.8M	$3.1M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE